| David Tobin Harrington, MD | |
|
2 Dudley St, Suite 470, Providence, RI 02905-3236 | |
| (401) 553-8314 | |
| (401) 868-2305 |
| Full Name | David Tobin Harrington |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 36 Years |
| Location | 2 Dudley St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558368092 | NPI | - | NPPES |
| 9020521 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD09639 (Rhode Island) | Primary |
| 2086S0102X | Surgery - Surgical Critical Care | MD09639 (Rhode Island) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Surgical Associates, Inc. | 4082503032 | 88 |
News Archive
By employing an immunoinformatics approach, a new study available on the preprint server bioRxiv* shows how the combination of peptides designed from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid phosphoprotein and spike glycoprotein may trigger an improved immunological response with respectable safety profile, informing, in turn, further vaccine development.
"The state's public employee unions won a major victory this week when the Legislature abandoned efforts to allow cities and towns to trim generous health care benefits enjoyed by thousands of municipal employees, retirees, and elected officials. The decision by lawmakers not to address the issue in next year's budget means the Legislature will almost certainly not act on it this year, setting the stage for mayors and other municipal officials to take their case directly to voters in a ballot initiative for 2012" (Murphy, 6/25).
Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.
The most personal encounter that many consumers have had so far with the much-heralded field of nanotechnology is the topic of an article in the current edition of Chemical & Engineering News (C&EN), the American Chemical Society's weekly newsmagazine.
› Verified 8 days ago
| Entity Name | University Surgical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376589895 PECOS PAC ID: 4082503032 Enrollment ID: O20040818001275 |
News Archive
By employing an immunoinformatics approach, a new study available on the preprint server bioRxiv* shows how the combination of peptides designed from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid phosphoprotein and spike glycoprotein may trigger an improved immunological response with respectable safety profile, informing, in turn, further vaccine development.
"The state's public employee unions won a major victory this week when the Legislature abandoned efforts to allow cities and towns to trim generous health care benefits enjoyed by thousands of municipal employees, retirees, and elected officials. The decision by lawmakers not to address the issue in next year's budget means the Legislature will almost certainly not act on it this year, setting the stage for mayors and other municipal officials to take their case directly to voters in a ballot initiative for 2012" (Murphy, 6/25).
Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.
The most personal encounter that many consumers have had so far with the much-heralded field of nanotechnology is the topic of an article in the current edition of Chemical & Engineering News (C&EN), the American Chemical Society's weekly newsmagazine.
› Verified 8 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154537520 PECOS PAC ID: 8921900044 Enrollment ID: O20141017000105 |
News Archive
By employing an immunoinformatics approach, a new study available on the preprint server bioRxiv* shows how the combination of peptides designed from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid phosphoprotein and spike glycoprotein may trigger an improved immunological response with respectable safety profile, informing, in turn, further vaccine development.
"The state's public employee unions won a major victory this week when the Legislature abandoned efforts to allow cities and towns to trim generous health care benefits enjoyed by thousands of municipal employees, retirees, and elected officials. The decision by lawmakers not to address the issue in next year's budget means the Legislature will almost certainly not act on it this year, setting the stage for mayors and other municipal officials to take their case directly to voters in a ballot initiative for 2012" (Murphy, 6/25).
Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.
The most personal encounter that many consumers have had so far with the much-heralded field of nanotechnology is the topic of an article in the current edition of Chemical & Engineering News (C&EN), the American Chemical Society's weekly newsmagazine.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Tobin Harrington, MD Po Box 16149, Rumford, RI 02916-0697 Ph: (401) 453-9625 | David Tobin Harrington, MD 2 Dudley St, Suite 470, Providence, RI 02905-3236 Ph: (401) 553-8314 |
News Archive
By employing an immunoinformatics approach, a new study available on the preprint server bioRxiv* shows how the combination of peptides designed from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid phosphoprotein and spike glycoprotein may trigger an improved immunological response with respectable safety profile, informing, in turn, further vaccine development.
"The state's public employee unions won a major victory this week when the Legislature abandoned efforts to allow cities and towns to trim generous health care benefits enjoyed by thousands of municipal employees, retirees, and elected officials. The decision by lawmakers not to address the issue in next year's budget means the Legislature will almost certainly not act on it this year, setting the stage for mayors and other municipal officials to take their case directly to voters in a ballot initiative for 2012" (Murphy, 6/25).
Optimer Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010. Optimer reported a net loss for the second quarter of 2010 of $10.4 million, or $0.27 per share, which was in line with the Company's expectations. This compares to a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share. The decrease in net loss was primarily due to lower research and development expenses offset by an increase in general and administrative expenses.
The most personal encounter that many consumers have had so far with the much-heralded field of nanotechnology is the topic of an article in the current edition of Chemical & Engineering News (C&EN), the American Chemical Society's weekly newsmagazine.
› Verified 8 days ago
Aileen Hsueh, Surgery Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-8450 Fax: 401-444-5088 | |
Liudmila Muraveika, Surgery Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5180 Fax: 401-444-6681 | |
Todd S Stafford, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 195 Collyer St Ste 302, Providence, RI 02904 Phone: 401-228-0633 Fax: 401-793-5171 | |
Sagar Mulay, Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5180 Fax: 401-444-6681 | |
Dewahar Senthoor, MD Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5471 Fax: 401-444-4557 | |
Chibueze Nwaiwu, MD Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5471 Fax: 401-444-4557 | |
Dr. Robert Ira Wolf, MD Surgery Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5180 |